Oxybutynin
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Oxybutynin: From Overactive Bladder to Restless Legs Syndrome
One-Sentence Summary
Oxybutynin is an antimuscarinic (M1/M3) receptor antagonist whose established pharmacology targets bladder detrusor overactivity, i.e. overactive bladder / urinary incontinence. The TxGNN model predicts potential efficacy for Restless Legs Syndrome, but this prediction is currently supported by 0 clinical trials and 0 publications, and the proposed target mechanism has no established pharmacological link to RLS pathophysiology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Overactive bladder / urinary incontinence (inferred from stated mechanism of action; no formal indication text available in regulatory data) |
| Predicted New Indication | Restless Legs Syndrome |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
A formal DrugBank mechanism-of-action record is not currently available for oxybutynin. Based on the mechanistic description accompanying this prediction, oxybutynin acts as a muscarinic (M1/M3) receptor antagonist, with its established pharmacological effect directed at reducing bladder detrusor muscle overactivity — the basis for its conventional use in overactive bladder and urinary incontinence.
Restless Legs Syndrome, however, is understood to arise primarily from central dopaminergic neurotransmission abnormalities and disrupted iron metabolism, not from peripheral or central muscarinic receptor activity. There is no established anticholinergic pathway implicated in RLS pathophysiology or its current treatment paradigm (dopamine agonists, alpha-2-delta ligands, iron repletion).
Given this, the very high TxGNN score (99.74%) should be interpreted as a statistical association derived from the knowledge graph’s structure rather than a mechanistically or clinically validated relationship. With zero supporting clinical trials and zero supporting publications, this combination — a high model score without mechanistic plausibility or empirical evidence — is a caution signal rather than a genuine repurposing lead, consistent with the assigned L5 evidence level and Hold recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Currently no marketing authorisation registered in Denmark. Market status: Not Marketed (0 authorisations).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a high TxGNN graph score alone, with no clinical trials, no supporting literature, and no established mechanistic pathway connecting oxybutynin’s antimuscarinic action to RLS pathophysiology. The drug is also not currently marketed in Denmark, and core safety data (warnings, contraindications, DDI) are entirely unavailable.
To proceed, the following is needed:
- Confirmed original indication and SmPC/label text (Danish or EU authorisation record)
- Verified mechanism-of-action data from DrugBank or an equivalent pharmacology source
- Danish/EU safety data: key warnings, contraindications, and drug interaction profile
- Preclinical or mechanistic evidence directly linking anticholinergic activity to an RLS-relevant pathway, before further clinical evaluation is warranted
- Note: a lower-ranked candidate indication in this evidence pack (peptic ulcer disease) has 3 supporting literature citations, though one reports oxybutynin-induced reflux esophagitis — a conflicting safety signal that would need separate evaluation if pursued
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.